logo
logo

Antidote Raises $23 Million To Scale Digital Patient Engagement Services

Jun 03, 2021•over 4 years ago

Amount Raised

$23 Million

Description

Antidote Technologies Limited (“Antidote”) today announced it has closed $23.2 million in funding to expand its digital patient engagement programs and clinical trial recruitment services. The funding round was led by LBO France, a private equity firm committed to supporting the growth of digital health, both in transforming health systems and accelerating medical R&D.

Company Information

Company

Antidote

About

Antidote is a digital health company on a mission to accelerate medical research. In a world where 80% of clinical trials are delayed or closed due to a shortage of suitable participants, Antidote uses precision recruitment to match the right patients with the right trials, striking the right balance between technology and human touch to deliver high-quality patient engagement. This is achieved through the integration of data-driven technologies, digital expertise, deep domain experience, an extensive diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit http://www.antidote.me.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech